A gene therapy for beta thalassemia will undergo ICER assessment for comparative clinical effectiveness and value. Betibeglogene autotemcel (Zynteglo/LentiGlobin) from Bluebird Bio will likely receive an FDA decision by mid-2022. ICER has released an outline of its strategy for the assessment. It will hold a public discussion during a New England CEPAC meeting in June 2022.
According to ICER, “All interested stakeholders are encouraged to submit comments and suggested refinements to the scope to ensure all perspectives are adequately considered. Comments can be submitted by email to firstname.lastname@example.org and must be received by 5 PM ET on December 16, 2021.”
Read more about the assessment and the public comment submission process by clicking here.
(Source: ICER, November 24th, 2021)